What is the recommended evaluation for a 6‑year‑old non‑verbal child with developmental delay and epilepsy since birth controlled with clobazam at bedtime, who sleeps 12 hours nightly and presents with fatigue, hyperactivity, mood lability, wandering attention, and mild hypotonia?

Comprehensive Sleep Evaluation with Actigraphy and Polysomnography

This 6-year-old with developmental delay, epilepsy controlled on clobazam, and symptoms of daytime fatigue, hyperactivity, mood lability, and hypotonia requires immediate evaluation for sleep disorders—particularly obstructive sleep apnea and circadian rhythm disturbances—using actigraphy and formal polysomnography, alongside screening for clobazam-related adverse effects and ADHD.

Primary Evaluation: Sleep Disorders

Sleep Study Workup

The constellation of 12 hours of sleep with persistent daytime fatigue, hyperactivity, and mood changes strongly suggests a primary sleep disorder rather than simply excessive sleep duration. Actigraphy should be initiated immediately for 1-2 weeks to objectively assess sleep-wake patterns, total sleep time, sleep onset/offset times, and sleep fragmentation 1. This is particularly valuable in children with developmental delays who cannot reliably self-report sleep quality.

Following actigraphy, formal polysomnography is essential to evaluate for:

• Obstructive sleep apnea (OSA): Common in children with hypotonia and developmental delays 2
• Central sleep apnea: Can occur with neurologic conditions
• Sleep architecture abnormalities: May explain non-restorative sleep despite adequate duration

The American Academy of Sleep Medicine specifically recommends actigraphy for pediatric patients with suspected circadian rhythm sleep-wake disorders, noting it provides objective data superior to sleep logs, particularly in children with developmental disorders 1.

Clobazam-Related Considerations

Critically evaluate clobazam as a contributor to symptoms. The FDA label explicitly lists sleepiness, tiredness, and behavioral changes (aggression, irritability, difficulty sleeping) as common adverse effects 3. The timing of clobazam administration (bedtime) may cause:

• Morning sedation/fatigue carrying into the day
• Paradoxical hyperactivity (documented adverse effect)
• Mood lability and irritability

Consider measuring clobazam and N-desmethylclobazam trough levels before the morning dose to assess for accumulation, particularly given the 12-hour sleep duration potentially affecting drug clearance patterns 4.

Secondary Evaluation: Neuropsychiatric and Metabolic Screening

ADHD Assessment

The hyperactivity and wandering attention warrant formal ADHD evaluation, but this must be distinguished from sleep deprivation effects, medication side effects, and underlying developmental disorder manifestations 5. Key differentiating features:

• Timing: Did hyperactivity predate current sleep issues or emerge concurrently?
• Setting: Present only at school or also at home during well-rested periods?
• Quality: True ADHD inattention versus fatigue-related attention lapses

Use standardized rating scales (Vanderbilt, Conners) from both parents and teachers 6. However, defer ADHD diagnosis and treatment until sleep disorders are addressed, as sleep deprivation mimics ADHD symptoms and treating ADHD with stimulants before correcting sleep disorders worsens outcomes.

Developmental and Neurologic Re-evaluation

Given the nonverbal status, lack of command-following, and hypotonia:

Obtain brain MRI if not done within past year to evaluate for:

• Structural abnormalities (polymicrogyria, heterotopia)
• Progressive changes
• Tethered cord (given hypotonia) 2

EEG to assess:

• Seizure control adequacy (subclinical seizures causing cognitive/behavioral symptoms)
• Sleep architecture on overnight EEG if polysomnography unavailable
• Epileptiform activity burden 7

Formal developmental assessment using age-appropriate standardized measures (e.g., Bayley Scales, Vineland Adaptive Behavior Scales) to establish baseline and identify specific domain deficits requiring intervention 8.

Metabolic and Endocrine Screening

Fatigue with hypotonia warrants:

• Thyroid function tests (TSH, free T4): Hypothyroidism causes fatigue, hypotonia, developmental regression
• Complete metabolic panel: Assess for electrolyte abnormalities, hepatic/renal dysfunction affecting drug metabolism
• Calcium and magnesium: Hypocalcemia can cause seizures and neuromuscular symptoms 2

Comorbidity Screening

Screen for anxiety and mood disorders using age-appropriate parent-report measures (CBCL, SCARED) 6. Mood lability may represent:

• Primary anxiety/mood disorder (common in epilepsy)
• Sleep deprivation effects
• Clobazam adverse effects
• Unrecognized absence seizures

Autism spectrum disorder screening should be completed if not previously done, given the developmental delays, nonverbal status, and behavioral concerns 9, 10.

Management Algorithm Based on Findings

If OSA Confirmed:

1. ENT referral for adenotonsillectomy evaluation
2. Consider CPAP if surgery contraindicated
3. Re-evaluate symptoms 6-8 weeks post-treatment

If Circadian Rhythm Disorder Identified:

1. Implement strict sleep hygiene and consistent sleep schedule
2. Consider melatonin 30-60 minutes before desired sleep onset (1-3 mg) 9
3. Light therapy in morning hours
4. Re-assess with repeat actigraphy in 4-6 weeks

If Clobazam-Related:

1. Do not abruptly discontinue (risk of status epilepticus) 3
2. Consider dose reduction or timing adjustment (split dosing vs. earlier evening dose)
3. Discuss alternative antiseizure medications with pediatric neurologist if symptoms persist
4. Monitor for withdrawal symptoms with any dose changes

If ADHD Confirmed After Sleep Optimization:

1. Behavioral interventions first (parent training, classroom accommodations) 6
2. If medication needed, methylphenidate shows effectiveness without significantly worsening seizures 5
3. Avoid atomoxetine initially (insufficient safety data in epilepsy)
4. Close monitoring of seizure frequency with any stimulant initiation

Critical Pitfalls to Avoid

• Do not attribute all symptoms to developmental delay without investigating treatable causes
• Do not start ADHD medications before addressing sleep disorders—this worsens outcomes and may precipitate seizures
• Do not assume 12 hours of sleep is adequate—quality matters more than quantity; fragmented sleep causes daytime dysfunction
• Do not overlook clobazam adverse effects—behavioral changes and sedation are common and dose-dependent 3
• Do not delay intervention services—refer to early intervention/special education regardless of diagnostic workup timeline 8

Immediate Next Steps

1. Order actigraphy for 1-2 weeks (can often be arranged through sleep medicine or neurology)
2. Schedule polysomnography (may have 2-3 month wait; initiate referral immediately)
3. Obtain clobazam levels, CBC, CMP, TSH, free T4 at next visit
4. Refer to developmental pediatrics for comprehensive assessment if not already established
5. Ensure early intervention services are in place for speech, occupational, and physical therapy 8

The high prevalence of sleep disorders in children with developmental delays and epilepsy (>50%) combined with the significant impact on quality of life, behavior, and cognition makes this evaluation urgent and high-yield 9, 2.